Trial Profile
A clinical trial of HER2.taNK cell therapy in patients with solid tumours
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2022
Price :
$35
*
At a glance
- Drugs HER2 taNK (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Feb 2018 New trial record